ClinicalTrials.gg
Not yet recruitingNCT07863102XR-PDUpdated Oct 7, 2026

Extended Reality Rehabilitation in Parkinson's Disease

An observational study in Parkinson Disease, sponsored by University Hospital, Ghent. Not yet recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University Hospital, Ghent · Observational

How we know

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Cross-sectional
Enrollment
15
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 82 studies in Parkinson Disease with a site in Belgium — 19 open to participants now, 23 under way, 2 of them phase 3. Parkinson Disease · Belgium.

Planned enrollment
16th of 17
15 · median 100
Started
2026
with 6 others
Observational
17 of 82
11 open now
Primary completion
2027-05
later than 9 of 22 live
Registered
82nd of 82
by date
Lead sponsor
3 of 82
University Hospital, Ghent

Among the 82 studies in Parkinson Disease with a site in Belgium, this one is the 16th largest by planned enrollment of the 17 observational ones that give a count, is one of 7 that started in 2026, is one of 17 observational ones, reaches primary completion later than 9 of the 22 other live ones, and was the 82nd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

19 of the 82 studies in Parkinson Disease with a site in Belgium are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Parkinson Disease with a site in Belgium, or all of them as a file.
02

Study summary

This study investigates how different types of extended reality, Virtual Reality (fully immersive) and Mixed Reality (partly real-world), can be used in rehabilitation for people with Parkinson's disease. Participants will attend a single 45-minute session at the Rehabilitation Center of UZ Ghent, where they will perform a simple balloon-popping task twice using a VR headset, once in each environment. During the exercises, they will be safely supported to prevent falls, while a wearable device measures physical responses such as heart rate and skin conductance. After each task, participants will complete short questionnaires about their experience and mental effort. The study aims to determine which type of extended reality is preferred and how each affects physical and mental responses, supporting the development of more accessible rehabilitation approaches.

Read the detailed description

Extended reality is being used increasingly within neurological rehabilitation. However, there are different forms of extended reality that can be used while wearing a head-mounted display (a VR headset). For example, sometimes the patient no longer sees the environment at all and is thus completely immersed in virtual reality (Virtual Reality), or sometimes the patient still sees part of the environment alongside the virtual reality (Mixed Reality). There are therapeutic arguments for using both forms, but to date, it is not known which is preferred for individuals with Parkinson's disease.

In a previous study (ONZ-2022-0404), a new type of therapy was tested in individuals with Parkinson's disease: visual perturbation training. This study took place in a large VR lab at Ghent University Hospital. To make this therapy accessible to more patients, this study will investigate the effect using a VR headset. Therefore, first the subjective preference in a small group of individuals with Parkinson's disease will be examined, and this study will also investigate whether there is a difference in the use of various forms of extended reality regarding a number of physical parameters (heart rate, heart rate variability, changes in skin conductance, etc.) measured in the patient using a wearable device, as well as mental load via questionnaires.

The participants will perform an exercise twice in which they have to pop balloons in a virtual world (Virtual Reality or Mixed Reality). During the exercise, participants will be secured in the Rysen, a weight-bearing system that ensures the participant cannot fall in the event of loss of balance. After each exercise, participants will complete the questionnaires on Redcap via a tablet provided by the department.

One test session lasts approximately 45 minutes.

All devices used (VR headset, Rysen weight-bearing system to guarantee patient safety, Shimmer to measure heart rate variability and skin conductance) are CE marked and are used within their scope. All tests will take place at the Rehabilitation Center of UZ Ghent. The VR headset and Rysen are devices owned by UZ Ghent. The Shimmer wearable is being made available by UGent for the duration of the study.

This information can help us with targeted follow-up research and applying for the necessary funding.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • PD
  • Extended Reality
  • Cognitive load
  • XR Rehabilitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Parkinson's Disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • you have been diagnosed with Parkinson's disease
  • you can walk independently without the use of aids
  • you are not experiencing pain at the time of the test
  • you are 18 years of age or older
  • you have normal or corrected normal (glasses/lenses) vision
  • you do not have a known, excessive susceptibility to motion sickness (e.g. car sickness)
  • you do not have a medication pump
  • you do not have a brain stimulator

Exclusion criteria

Exclusion Criteria:

  • you have a known, excessive sensitivity to motion sickness (e.g. car sickness)
  • you have a medication pump
  • you have a brain stimulator
05

Study design

Observational model
Case-crossover
Time perspective
Cross-sectional
Enrollment
15 participants (estimated)
Patient registry
No

Groups and cohorts

  • Within-Subject XR (VR and MR)

    Participants complete two conditions during a single study session using a head-mounted display, a Virtual Reality (fully immersive) and Mixed Reality (real-world view combined with virtual elements) tasks. The order of conditions is varied. During both conditions, participants perform a standardized balloon-popping task while seated in a weight-support system to ensure safety. Physiological responses (heart rate, heart rate variability, and skin conductance) are recorded, and subjective experience and mental load are assessed via questionnaires after each condition.

    Device: Extended reality balance training

Interventions

  • DeviceExtended reality balance training

    Participants perform a balloon-popping task for balance training using a VR headset in two conditions: Virtual Reality (fully immersive) and Mixed Reality (real-world combined with virtual elements). The task includes visual changes to challenge how participants see and respond to their environment, including eye movements. The goal is to compare how these two formats affect mental effort and experience.

06

What researchers measure

Primary outcomes

  1. Score on the Igroup presence questionnaire (IPQ)

    The Igroup Presence Questionnaire (IPQ) is a scale for measuring the sense of presence experienced in a virtual environment. It will be used as one of the measures to identify the subjective preference during Virtual Reality (fully immersive) and Mixed Reality (real-world combined with virtual elements). This questionaire consists of 14 items where participants indicate their spatial presence, involvement or realness on a Likert scale (1-7). Max score is 98. Higher score is higher feeling of presence, immersion and engagement.

    Time frame: Immediately after each condition (within one study session)

  2. Score on the NASA Task Load Index (Nasa-TLX)

    The NASA-TLX is a questionnaire to examine the subjective workload. It contains 6 items where participants again score each item on a 7 point Likert scale. A higher score indicates more cognitive workload.

    Time frame: Immediately after each condition (within one study session)

  3. Score on the Virtual Reality Sickness Questionnaire

    Questionnaire to document potential side effects of using extended reality (e.g. cybersickness). Participants are asked to indicate for 9 symptoms on a 4 point Likert scale if they experience side effects and how intense they are present. A higher score indicates more adverse events.

    Time frame: Immediately after each condition (within one study session)

  4. Hartrate (variability) during the extended reality sessions

    Physiological responses during VR and MR conditions are measured continuously using a wearable device. These measures reflect autonomic nervous system activity and objective load during task performance. Differences between VR and MR conditions will be analyzed.

    Time frame: During the MR and VR condition (within one study session)

  5. Skin conduction during the extended reality sessions

    Physiological responses during VR and MR conditions are measured continuously using a wearable device. These measures reflect autonomic nervous system activity and objective load during task performance. Differences between VR and MR conditions will be analyzed.

    Time frame: During the MR and VR condition (within one study session)

Secondary outcomes

  1. Eye tracking during the extended reality task as a measure of visual function

    Exploration of the relationship between visual function and subjective cognitive load scores obtained after the MR condition, to assess whether eye movement behavior contributes to perceived mental effort.

    Time frame: During the MR session

  2. Education level

    Participants will be questioned to know their highest education level. This will be used to assess if this a co-variate for the primary outcome measures

    Time frame: Before the intervention

  3. Experience with the use of extended reality

    Participants will be questioned to know if they have any experience using extended reality. This will be used to assess if this a co-variate for the primary outcome measures

    Time frame: Before the intervention

  4. Technological skilled

    Participants will be questioned to know if they consider themselves technological skilled. This will be used to assess if this a co-variate for the primary outcome measures

    Time frame: Before the intervention

07

Study locations

1 site
  • UZ Ghent
    Ghent, 9000, Belgium
    • Sophie De Mits · ContactSophie.DeMits@uzgent.be · 09 332 12 43
    • Sophie De Mits · Principal investigator
    • Lode Sabbe · Sub investigator
    • Sam Van Damme · Sub investigator
    • Femke De Backere · Sub investigator
    • Anke Van Bladel · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for May 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Oct 7, 2026
StartEst.
Oct 2026
Primary completionEst.
May 2027
CompletionEst.
Sep 1, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07863102
Collaborators
University Ghent
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Oct 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion